Arrhythmogenic remodeling of β2 versus β1 adrenergic signaling in the human failing heart

Circ Arrhythm Electrophysiol. 2015 Apr;8(2):409-19. doi: 10.1161/CIRCEP.114.002065. Epub 2015 Feb 11.

Abstract

Background: Arrhythmia is the major cause of death in patients with heart failure, for which β-adrenergic receptor blockers are a mainstay therapy. But the role of β-adrenergic signaling in electrophysiology and arrhythmias has never been studied in human ventricles.

Methods and results: We used optical imaging of action potentials and [Ca(2+)]i transients to compare the β1- and β2-adrenergic responses in left ventricular wedge preparations of human donor and failing hearts. β1-Stimulation significantly increased conduction velocity, shortened action potential duration, and [Ca(2+)]i transients duration (CaD) in donor but not in failing hearts, because of desensitization of β1-adrenergic receptor in heart failure. In contrast, β2-stimulation increased conduction velocity in both donor and failing hearts but shortened action potential duration only in failing hearts. β2-Stimulation also affected transmural heterogeneity in action potential duration but not in [Ca(2+)]i transients duration. Both β1- and β2-stimulation augmented the vulnerability and frequency of ectopic activity and enhanced substrates for ventricular tachycardia in failing, but not in donor, hearts. Both β1- and β2-stimulation enhanced Purkinje fiber automaticity, whereas only β2-stimulation promoted Ca-mediated premature ventricular contractions in heart failure.

Conclusions: During end-stage heart failure, β2-stimulation creates arrhythmogenic substrates via conduction velocity regulation and transmurally heterogeneous repolarization. β2-Stimulation is, therefore, more arrhythmogenic than β1-stimulation. In particular, β2-stimulation increases the transmural difference between [Ca(2+)]i transients duration and action potential duration, which facilitates the formation of delayed afterdepolarizations.

Keywords: arrhythmia (mechanisms); calcium; heart failure; receptors, adrenergic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Adrenergic beta-1 Receptor Agonists / pharmacology
  • Adrenergic beta-2 Receptor Agonists / pharmacology
  • Arrhythmias, Cardiac / diagnosis
  • Arrhythmias, Cardiac / etiology*
  • Arrhythmias, Cardiac / metabolism
  • Arrhythmias, Cardiac / physiopathology
  • Calcium Signaling* / drug effects
  • Case-Control Studies
  • Heart Failure / complications*
  • Heart Failure / diagnosis
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Heart Failure / surgery
  • Heart Transplantation
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism*
  • Heart Ventricles / pathology
  • Heart Ventricles / physiopathology
  • Humans
  • Phosphorylation
  • Receptors, Adrenergic, beta-1 / drug effects
  • Receptors, Adrenergic, beta-1 / metabolism*
  • Receptors, Adrenergic, beta-2 / drug effects
  • Receptors, Adrenergic, beta-2 / metabolism*
  • Risk Factors
  • Time Factors
  • Ventricular Function, Left* / drug effects
  • Ventricular Remodeling* / drug effects
  • Voltage-Sensitive Dye Imaging

Substances

  • ADRB1 protein, human
  • ADRB2 protein, human
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-2 Receptor Agonists
  • Receptors, Adrenergic, beta-1
  • Receptors, Adrenergic, beta-2